Limitations, agreements, and source contact

Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer · Source last updated 2015-11-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restriction Type

LTE60

restrictive Agreement

true

point Of Contact

email

gfleming@medicine.bsd.uchicago.edu

organization

University of Chicago Comprehensive Cancer Center

phone

773-702-6712

title

Dr. Gini Fleming

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice